Librela 10mg 2x1ml vials

Librela – Injectable Pain Relief for Degenerative Joint Disease in Dogs Librela is a monoclonal antibody treatment administered once a month, designed to control pain associated with degenerative joint disease (OA) in dogs. Librela works by targeting Nerve Growth Factor (NGF), a key contributor to degenerative joint disease pain, helping to improve comfort, mobility, and quality of life. Main Benefits: Provides long-term control of degenerative joint disease pain. Administered once a month by a veterinarian. Targets NGF involved in pain signaling. Helps improve daily mobility and comfort. Indication: Pain control associated with degenerative joint disease in dogs. Administration: Monthly injection under veterinary supervision.